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ABSTRACT
We characterized the temporal changes in chondrogenic genes and developed a staging scheme for in vitro
chondrogenic differentiation of human mesenchymal stem cells (hMSCs) in three-dimensional (3D) algi-
nate gels. A time-dependent accumulation of glycosaminoglycans, aggrecan, and type II collagen was
observed in chondrogenic but not in basal constructs over 24 days. qRT-PCR demonstrated a largely
characteristic temporal pattern of chondrogenic markers and provided a basis for staging the cellular
phenotype into four stages. Stage I (days 0–6) was defined by collagen types I and VI, Sox 4, and BMP-2
showing peak expression levels. In stage II (days 6–12), gene expression for cartilage oligomeric matrix
protein, HAPLN1, collagen type XI, and Sox 9 reached peak levels, while gene expression of matrilin 3,
Ihh, Homeobox 7, chondroadherin, and WNT 11 peaked at stage III (days 12–18). Finally, cells in stage IV
(days 18–24) attained peak levels of aggrecan; collagen IX, II, and X; osteocalcin; fibromodulin; PTHrP;
and alkaline phosphatase. Gene profiles at stages III and IV were analogous to those in juvenile articular
and adult nucleus pulposus chondrocytes. Gene ontology analyses also demonstrated a specific expression
pattern of several putative novel marker genes. These data provide comprehensive insights on chon-
drogenesis of hMSCs in 3D gels. The derivation of this staging scheme may aid in defining maximally
responsive time points for mechanobiological modulation of constructs to produce optimally engineered
tissues.
INTRODUCTION
ARTICULAR CARTILAGE is an avascular connective tissuepopulated by highly specialized cells of mesenchymal
origin. These chondrocytes are responsible for producing,
sustaining, and degrading an extensive cartilage-specific
extracellular matrix (ECM).1 The ECM in healthy cartilage
provides it with the shape stability and strength to sustain the
complex loads that facilitate smooth skeletal movement. In
spite of its durability, mature cartilage is vulnerable to in-
juries and disease processes that cause irreversible tissue
damage because of its limited capacity for self-repair.2 At-
tempts to augment cartilaginous healing responses in both
experimental animal models and arthritis patients have uti-
lized two fundamentally different strategies, namely, (1)
stimulation of regeneration in situ (e.g., periosteal and peri-
chondral tissue grafting, subchondral penetration, artificial
matrices, chondrogenic cell transplantation, and growth
factor utilization) or (2) transplantation of replacement tis-
sues (e.g., autografts and allografts).2–8 These methods
generally produce fibrous tissue that lacks the desired me-
chanical and morphological characteristics of normal artic-
ular cartilage.
Recently, cell-based techniques that utilize a three-
dimensional (3D) carriermimicking the physiologicalmilieu
are demonstrating promise. These approaches incorporate
cells such as chondrocytes, periosteocytes, or perichondro-
cytes into a variety of carrier systems including alginate,
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fibrin, hyaluronate, collagen gels, or biodegradable macro-
molecular polymers.9–16Additionally, numerous growth fac-
tors and cytokines, such as members of transforming growth
factor superfamily (TGF-b1, -b2, and -b3; BMP-2, -6, and
-7), have demonstrated an encouraging capacity for chon-
drogenic induction.17–20 Unfortunately, the slow in vitro
propagation of adult chondrocytes has limited their wide-
spread use in cartilage regeneration techniques.
Human mesenchymal stem cells (hMSCs) have become a
popular choice for cartilage tissue engineering given their
capacity of rapid in vitro proliferation and lineage differ-
entiation into chondrocytes.17–19 Because hMSCs encapsu-
lated in alginate beads can form cartilage, this system is used
commonly to study the molecular mechanisms involved
in chondrogenesis and endochondral ossification.18,19 While
the progression of chondrogenic differentiation has been
generally described for this system, cellular phenotypes and
temporal patterns of relevant gene expression have not been
presented quantitatively or comprehensively. Such data
would provide a solid foundation upon which to rationally
explore and optimize in vitro factors that guide chondrogenic
differentiation, such asmechanical or biologicmanipulation.
To better understand the process of chondrogenic differ-
entiation of hMSCs in a 3D carrier system amenable to
in vitro manipulation, and to better define temporal aspects
of relevant gene expression and phenotypic changes, we
studied differentiating hMSCs in alginate gel discs at four
distinct time points ranging from day 0 to 24, using both
traditionally defined markers and global gene expression
profiles. Our results present a well-characterized system in
which hMSCs in 3D alginate culture system demonstrate
distinct stages of chondrogenic differentiation.
MATERIALS AND METHODS
hMSC-alginate gel/cell cultures
hMSCs, cell culture media, and supplements were ob-
tained from Cambrex Bio Science (Walkersville, MD), and
chemical reagents were purchased from Sigma-Aldrich
(St. Louis, MO) unless otherwise mentioned. On the basis of
their surface markers and their capability for multipotential
differentiation,21 these cells have been previously character-
ized as stem cells. The capacity of the cells used in our
experiments to undergo multipotential differentiation (chon-
drogenesis, osteogenesis, and adipogenesis) under appropri-
ate conditions was further confirmed by preliminary studies
(data not shown).
hMSCs were expanded in monolayer culture by passaging
three times inMSC basal medium (MSCBM)with 10%FBS.
The cells (106 cell/mL) were suspended in 2% alginate (w/v)
solution, the suspension was loaded into dialysis tubing
(10,000 molecular weight cut-off) (Spectrum Laboratories,
Rancho Dominguez, CA), and the tubing was soaked in
102mM calcium chloride with swirling for 40min. The
gelled constructs were washed with HEPES solution, and cut
into cylindrical discs (6mm in diameter and 2mm in height).
After recovery in MSCBM for 24 h, considered day 0, the
cell/gel constructs were separated into two groups: the
chondrogenic constructs were cultured in serum-free hMSC
chondrogenic medium containing 107M dexamethasone,
50mg/mL ascorbate, 50mg/mL Insulin-transferrin sodium
selenite, 100mg/mL sodium pyruvate, 40mg/mL proline,
2mM L-glutamine, and 10 ng/mL TGF-b3; the baseline
controls were cultured in MSCBM plus 10% FBS. The
medium was changed every other day, and constructs were
retrieved at days 0, 6, 12, 18, and 24 of culture for assaying.
Cell proliferation and viability
The proliferation of hMSCs was assayed using alamar-
Blue assay kit (Biosource, Camarillo, CA). Briefly, cell/gel
constructs were washed in PBS and incubated with 300 mL
alamarBlue solution for 1 h. The fluorescence of reduced
alamarBlue in the solution was determined using a spec-
trophotometer (MolecularDevices, Sunnyvale,CA) atwave-
lengths of 530-nm excitation and 600-nm emission. After
PBS wash, hMSCs were released by incubating gels with
55mM sodium citrate solution and the cell lysates were
subjected to BCA protein assay (Pierce, Rockford, IL) to
standardize alamarBlue fluorescence data.
Cell viability was assayed by LIVE/DEAD staining as per
the manufacturer’s instructions (Molecular Probes, Sunny-
vale, CA). The central parts of constructs were sliced (0.1-
mm thick), washed with HBSS, and staining solution added.
After 20-min incubation in darkness, the slices were washed
with HBSS before observation under a fluorescent micro-
scope (Nikon TS100, Tokyo, Japan). Cell viability was semi-
quantified as the percentage of live (green-stained) cells
relative to the total number of live and dead (red-stained)




The distribution of hMSCs in constructs and the cellular
morphology were examined using hematoxylin and eosin
(H&E) staining. Newly synthesized cartilage ECM gly-
cosaminoglycans (GAGs) were visualized by Safranin-O
staining. Briefly, paraformaldehyde-fixed constructs were
encased in agarose and then embedded in paraffin, sectioned
and subjected to routine Safranin-O staining as described
previously,9,19 and mounted with coverslips prior to photo-
micrography.
To localize collagen type II and aggrecan, sections were
rehydrated prior to immunostaining with Histostain-SP kit
(Invitrogen, Carlsbad, CA). The epitopes for aggrecan and
type II collagen were exposed by treating the sections with
either chondroitinase ABC or pepsin, respectively. Endo-
genous peroxidase was then quenched, and the sections were
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incubated with a blocking solution, followed by incubation
with primary antibodies specific for human collagen type II
(Chemicon International, Temecula, CA) or aggrecan (Ab-
cam, Boston, MA). Sections were washed, incubated with
biotinylated secondary antibody,washed again, and incubated
with a streptavidin-peroxidase conjugate. Following further
washing, sections were incubated with diaminobenzidine
solution, and counterstained with hematoxylin. Negative
control sections were incubated with nonimmune serum.
Quantitative real-time PCR (qRT-PCR)
and RT-PCR analyses
Total RNAwas extracted from constructs, and from freshly
liberated primary human juvenile articular chondrocytes,
fibroblast-like annulus fibrosus cells, and chondrocyte-like
nucleus pulposus cells of adult human intervertebral discs22
using RNeasy Mini kit (Qiagen, Valencia, CA). The latter
three cell types were used to provide comparative data for the
differentiating hMSCs. Juvenile chondrocytes (kindly pro-
vided by ISTO Technologies, St. Louis, MO) were harvested
from articular cartilage of human donors ranging in age from
birth to 3 years as previously described.23 Adult nucleus
pulposus and annulus fibrosus cells were isolated from normal
tissues collected at the time of spine fusion surgery (29-year-
old male [nucleus] and 51-year-old male [annulus]) after
approval by the UCSF institutional review board.
Because of the small size of the gels and low RNA yield,
RNA was pooled from each of 20 chondrogenic or 20 basal
constructs. Total RNA (1mg) from the constructs and from
primary cells was reverse transcribed using Ominiscript RT
Kit (Qiagen). A 1:100 dilution of the resulting cDNA was
utilized as a template to quantify the relative content of
mRNA by qRT-PCR (ABI PRISM 7500, Applied Biosys-
tems, Carlsbad, CA) for the genes listed in Table 1. The
specific primers designed with Primer Express 2.0 (Applied
Biosystems) are also listed in this table. PCR reactions were
performed with SYBR green PCR master mix kit (Applied
Biosystems). 18 S rRNA was used as an internal control.
Cycle threshold values of the genes of interest and the
quantitative gene expression levels relative to 18 S rRNA in
the samples were determined as per ABI System instructions.
RT-PCR was employed to validate the expression pattern
of key cartilage-marker genes, including collagen types IIa1
and Xa1, cartilage oligomeric matrix protein (COMP), and
aggrecan in both basal and chondrogenic hMSCs. The pro-
cedures for reverse transcription of total RNA and subse-
quent dilution of synthesized cDNA were performed as
described above. PCR amplification was performed using
Taq PCR master mix kit (Qiagen) using the following con-
ditions: 948C for 4min, followed by 25 cycles at 948C for
25 s, 538C for 30 s, and 728C for 45 s, and final extension at
728C for 10min. Human glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was used as an internal control. The
specific primers used for RT-PCR were as follows: colla-
gen type IIa1, 50-ACC CCA ATC CAG CAA ACG TT-30
(forward) and 50-ATC TGG ACG TTG GCA GTG TTG-30
(reverse); collagen type Xa1, 50-AGG TGC CAA AGG
GGA ACA AG-30 (forward) and 50-AAT CCT GGA ATG
CCT GGT GG-30 (reverse); COMP, 50-AGG ACA ACT
GCG TGA CTG TG-30 (forward) and 50-GTG TCC TTT
TGG TCG TCG TT-30 (reverse); aggrecan, 50-CCT CTG
GAC AAC CAG GTG TT-30 (forward) and 50-AAA CCA
GGT CAG GGA CTC CT-30 (reverse); GAPDH, 50-GAG
TCA ACG GAT TTG GTC GT-30 (forward) and 50-TTG
ATT TTG GAG GGA TCT CG-30 (reverse).
Microarray analysis
As a complement to the qRT-PCR experiments, and to
identify putative novel marker genes that may be specific to
particular hMSC chondrocytic differentiation stages, we an-
alyzed global gene expression patterns bymicroarray (Human
U133 plus 2.0. containing 54,675 probe sets plus 62 control
sets; Affymetrix, Santa Clara, CA). Total RNA was pooled
from 20 constructs and cleaned by using RNeasy Mini kit
(Qiagen) and assayed to confirm quality (Agilent 2100
BioAnalyzer, Santa Clara, CA). Double-stranded cDNA was
prepared using an oligo(dT)-T7 RNA polymerase primer.
Biotinylated cRNA was prepared by in vitro transcription,
and the resulting RNA was fragmented by partial hydro-
lysis. Hybridization signal was obtained by staining with
phycoerythrin-streptavidin (GeneChip Fluidics Station, Affy-
metrix). The tagged cRNA was hybridized to microarrays,
and differential gene expression levels were assessed using
Affy/affyPLMpackage andRMA(robustmultiarrayaverage)
intensity in log2 scale for each probe set (gene). Essentially,
the 11 perfect-match intensities per probe set were (1) back-
ground corrected, (2) quantile normalized, and (3) summa-
rized for each probe set using a robust fit of linear models as
described.24 A total of nine arrays were used, one for each
condition and time point. Genes with contradictory multiple
positive probes sets were not included in the results. Onto-
logical analysis was performed using GOstat and DAVID
software and the Gene-Ontology database publicly available
through the Gene Ontology Project.25
To identify genes that may be putative unique markers for
each differentiation stage, we first identified genes that were
more than twofold up- or downregulated in chondrogenic
media relative to basal media at the same time point. We
further identified genes that were at least twofold more up-
or downregulated at one stage relative to any other stage.
Because many genes fit these criteria for days 6 and 24,
while few did for days 12 and 18, we refined the selection
criterion to exclude genes less than fivefold up- or down-
regulated at days 6 and 24. This resulted in a manageable
number of genes for all time points. These data were also
utilized to derive gene ontology patterns.
Statistical analysis
Proliferation of hMSCs at individual time points in both
basal and chondrogenic group was compared to that on day 0



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































670 XU ET AL.
using single factorial analysis of variance (ANOVA). Gene
expression of aggrecan, COMP, collagen type II, and col-
lagen type X on days 6, 12, 18, and 24, respectively, in
chondrogenic group and their corresponding time point in
basal group were analyzed using Student’s t test.
RESULTS
hMSCs show mildly diminished viability
and progressive reduction in proliferation
in long-term 3D cultures
Cell proliferation was slightly, but not significantly, lower
at day 6 in both the basal and chondrogenic media relative to
the baseline controls (Fig. 1A). In contrast, constructs cul-
tured in both media had significantly lower cell proliferation
at days 12, 18, and 24 relative to that at day 0. By day 24, the
proliferation was reduced to 61.5% for the basal group and
76.9% for the chondrogenic group relative to day 0 cultures.
Under both basal and chondrogenic conditions, while a
small number of dead cells were observed, cell viability
remained relatively stable during the experimental period
(Fig. 1B). Relative to baseline levels on day 0, there was a
gradual but insignificant reduction in cell viability of 14% in
basal group and 18% in chondrogenic group on day 24 (Fig.
1C). The cell viability and proliferation showed no statisti-
cally significant differences between the basal and chon-
drogenic media at any time point.
Cartilage-specific ECMs are accumulated
in TGF-b3–stimulated hMSC/gel constructs
We next utilized histology and immunohistochemistry to
assess the temporal changes in cell morphology and distri-
bution of cartilaginous markers in constructs. H&E staining
showed homogenous cell distribution in both basal and
chondrogenic constructs (Fig. 2A). While there was little
change in cellular morphology in basal conditions, cells in
chondrogenic media were observed to have large nuclei and
became progressively bigger and more rounded over 24 days
of culture. Clear pericellular lacunaewere also observed in the
chondrogenic construct but not in the basal construct. Con-













































FIG. 1. hMSCs in alginate gels show decreased proliferation and minimal changes in cell viability over 24 days of culture. The
proliferation of hMSCs in alginate gels, determined by alamarBlue staining, was significantly reduced from day 0 to 24 in both basal and
chondrogenic constructs (A). However, there was no significant difference in cell proliferation between the two groups at any of the time
points. (B) LIVE/DEAD fluorescent staining performed on slices of constructs showed a few dead cells (red) as compared to live cells
(green). Semiquantitative analysis of these sections showed relatively stable cell viability in both groups from day 0 to 24 (C). Data were
obtained from at least four cell/gel constructs, and expressed as mean SD (*p 0.01 vs. proliferation on day 0; magnification10; bar
represents 100 mm).
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a temporal increase of staining in chondrogenic constructs,
indicating increasing accumulation of GAGs (Fig. 2B). In
contrast to the chondrogenic constructs, none of the basal
constructs showed positive staining with Safranin-O.
Immunohistochemistry to aggrecan and type II collagen
confirmed the presence of cartilage-specific ECM macro-
molecules in chondrogenic constructs (Fig. 2C and D,
respectively). These matrix molecules were detected intra-
cellularly and pericellularly starting as early as day 6 in
chondrogenic constructs. At subsequent time points, ag-
grecan and type II collagen stainings were observed both
intracellularly and within the lacunae enclosing chon-
drogenic cells. In contrast to the generalized and intense
Safranin-O staining, which depicts the binding of the dye to
the large number of anionic molecules in GAGs, the sparse
distribution of aggrecan staining can likely be explained by
relatively limited binding of the antibody to specific epitopes
of the molecule.
Chondrogenic conditions promote
the progressive chondrocytic differentiation
of hMSCs in alginate gels
Both RT-PCR (Fig. 3A) and qRT-PCR (Fig. 3B–E) were
used to assess the temporal gene expression of four key
chondrocyte markers, namely, collagen types II and X,
COMP, and aggrecan in the cells. These assays revealed that
all four markers had temporally distinct patterns of induction
in cells from chondrogenic constructs. COMP showed an
early upregulation peaking at approximately 63-fold on day
12. Aggrecan mRNA levels increased significantly by day
12, followed by a continued gradual increase until day 24 of
culture. Collagen type II was highly upregulated by as much
as 35-fold by day 6 and 91-fold by day 12 of culture.
However, its peak induction of about 1200-fold at day 24
dwarfs this significant early upregulation. Finally, collagen
type X showed an approximate 30-fold induction at days 12
and 18 and peaked to a 165-fold induction by day 24. All
four markers showed minimal changes in basal conditions,
validating that the chondrogenic media indeed modulate
chondrogenesis of these hMSCs.
Next, a comprehensive quantitative assessment of chan-
ges in a larger pool of chondrogenic markers in the hMSCs
was performed by qRT-PCR. For the 21 genes that were
examined by this method, the percent fold change in each
gene was standardized relative to the peak levels considered
to be 100%, and the genes arranged in descending order from
the one that first reaches 81–100% levels to one reaching this
level last (Fig. 4). Analysis of individual genes revealed
varied patterns of gene regulation over the experimen-
tal period. Thus, although many genes including COMP,
HAPLN1, WNT 11, aggrecan, collagen types II and X, os-
teocalcin, parathyroid hormone-related protein (PTHrP),
and alkaline phosphatase showed progressive increases in
expression levels over the entire experimental period, other
genes had bimodal patterns of induction. The genes in the
latter group included collagen type VI (peaking on days 0
and 18), Sox 4 (days 0 and 18), and Sox 9 (days 12 and 24).
Amongst the genes demonstrating a progressive increase
over the 24 days, some such as collagen type X had a gradual
increase in levels, while others such as matrilin 3, Ihh,
Homeobox 7, chondroadherin, WNT 11, PTHrP, collagen
type IX, and alkaline phosphatase demonstrated a steep
upregulation. Other patterns of gene expression included a
peak during mid-stages of the experiment followed by a
decrease often to baseline levels, such as that for BMP-2 and
collagen type I, both of which peaked at day 6. Similarly,
matrilin 3, Ihh, Homeobox 7, and chondroadherin had peak
expression levels at day 18 and then decreased at day 24.
The sequential organization of the genes based on the
specific time point that each first reached 81–100% ex-
pression levels enabled the derivation of a four part–staging
scheme for chondrocytic differentiation of hMSCs in 3D
gels (Fig. 4). This analysis revealed that collagen type VI,
Sox 4, BMP-2, and collagen I were at peak levels between
days 0 and 6, which was defined as stage I, while COMP,
HAPLN1, collagen type XI, and Sox 9 first reached peak
levels by day 12, designated as stage II. Similarly, stage III
was designated when matrilin 3, Ihh, Homeobox 7, chon-
droadherin, and WNT 11 first attained peak levels at day 18.
Finally, stage IV was designated when aggrecan; collagen
types II, IX, and X; osteocalcin; fibromodulin; PTHrP; and
alkaline phosphatase peaked at day 24.
Chondrogenically differentiating hMSCs
in 3D gels show similarities in stage-dependent
profiles of chondrocyte markers to those
of primary chondrocytic cells
Using qRT-PCR, we next assessed what similarities exist
between gene profiles at various stages of chondrogenic
differentiation of hMSCs in 3D gels to those in primary
chondrocytic cells freshly isolated from juvenile knee joint
articular cartilage and adult nucleus pulposus as well as
fibroblast-like cells from the annulus fibrosus (Table 2). In
general, the mRNA levels for most genes assayed in the two
primary chondrocytic cells were between 20% and 50% of
the peak levels found in chondrogenic hMSCs. The notable
exceptions to this were Sox 9, chondroadherin, and alkaline
phosphatase, which had similar absolute levels in chondro-
genic hMSCs and one or both types of chondrocytic cells.
Additionally, matrilin 3 and osteocalcin levels were 4-fold
and 20-fold greater, respectively, in nucleus pulposus cells
than the peak levels in hMSCs. While the absolute levels of
gene expression differed between the hMSCs and those
of cells in vivo, and also in some cases between the two types
of primary chondrocytic cells, an assessment of expression
profiles revealed interesting relationships between the three
types of primary cells and hMSCs at various stages of
chondrocytic differentiation. The profiles of the select genes
in day-0 hMSCs, characterized by a high expression of
collagen type VI and Sox 4, and low expression of most
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cartilage-related genes exceptWNT 11, collagen type II, and
PTHrP, were most similar to those in annulus fibrosus
fibroblast-like cells. Day-6 hMSCs showed gene profiles
intermediate between those of annulus fibrosus cells and
those from juvenile chondrocytes and nucleus pulposus
cells. Exceptions to these similarities between the day-6
hMSCs and annulus fibrosus cells were that the hMSCs
showed higher levels of type XI collagen and aggrecan
mRNAs than those found in the annulus fibrosus cells.
Starting from day 12 to the end of the experimental period,
cells from chondrogenic hMSC constructs showed gene
profiles similar to those observed in juvenile chondrocytes
and nucleus pulposus cells. Exceptions to these similarities
were the low levels of Homeobox 7 and alkaline phospha-
tase in juvenile chondrocytes, which was not the case in the
day-18 and -24 chondrocytic hMSCs. Overall, the findings
demonstrated that the gene profiles in hMSCs at the early















Day 6 Day 12 Day 18 Day 24
Day 6 Day 12 Day 18 Day 24 -ve Control
FIG. 2. hMSCs in chondrogenic constructs show distinctly different cellular morphology and distribution of cartilage-specific ECM
from those in basal constructs. Cell/gel constructs were sectioned and subjected to H&E staining and Safranin-O staining. Immuno-
histochemistry was also performed to detect aggrecan and collagen type II. (A) H&E staining showed homogenous cell distribution in
both basal and chondrogenic constructs, with the cells in chondrogenic media becoming progressively bigger and more rounded over 24
days of culture. Clear pericellular lacunae were also observed in the chondrogenic construct but not in the basal construct. (B) The
accumulation of cartilage ECM was confirmed by Safranin-O staining, which revealed progressive increase in GAG staining in
chondrogenic construct but not in basal construct during the experimental period. (C) Aggrecan and (D) collagen type II were primarily
localized intracellularly at days 6 and 12 of chondrogenic cultures. At later time points, these matrix molecules showed increasing
intracellular and pericellular staining to form distinguishable lacunae embracing the cells. Negative controls were incubated with
nonimmune serum. (Arrows point to the positive staining; magnification20; scale bars represent 50 mm.)
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those of fibroblast-like annulus fibrosus cells, while those of
hMSCs at day 12 and after of chondrogenic differentiation
had gene profiles more similar to those of chondrocytic cells.
Putative novel markers for hMSC chondrogenic
differentiation based on global gene
expression patterns
To identify putative novel markers unique to the indi-
vidual chondrogenic stages designated in this study, we as-
sayed global gene expression patterns at each of the four
differentiation stages by microarray and developed an ap-
propriate shortlist of genes by the analysis described in the
‘‘Materials and Methods’’ section. Based on historical data,
of all the genes on this list, approximately one-third had
some known functional link to chondrogenesis, or highly
related processes, while the remainder appeared to have no
prior linkage to chondrogenic processes. Since the purpose
of this analysis was to identify putative novel markers as-
sociated with different stages of chondrogenic differentia-
tion, the data presented here focus on the latter set of genes.
Analysis of this set of 29 stage-specific genes revealed en-
richment of several functional categories relevant to chon-
drogenesis and/or chondrocyte physiology (Table 3). These
functional categories include skeletal development (four
genes), ECM (eight genes), and proteolysis/cytokine activity
(four genes). A highly represented functional ontology
grouping of more general interest, namely, cell communi-
cation (11 genes), was also included. Consistent with the
emergence of a more highly differentiated phenotype in the
latter stages of our time course, all genes linked to skeletal
development, and the majority of those linked to the ECM,
were upregulated at day 24. Other functional ontologies
were represented by genes differentially expressed at vari-
ous stages. Changes in gene expression observed in this
microarray analysis trended highly toward downregulation
of genes at the earliest time point (day 6) and upregulation of





















































































































FIG. 3. Cartilage-specific genes undergo temporal upregulation during differentiation of hMSCs in 3D alginate gels. Total RNA
extracted from 20 cell/gel constructs incubated in basal or chondrogenic media for up to 24 days was subjected to RT-PCR (A) and qRT-
PCR (B) for aggrecan, COMP, collagen types II, and X. (A) Chondrogenic constructs showed early significant increases in expression of
COMP and collagen type II, which peaked at 12 and 24 days of culture, respectively. Aggrecan and type X collagen mRNA expression
levels were significantly elevated by 12 days of culture and reached peak levels by 24 days. Cells incubated in basal media showed no
induction in any of these markers. Data were expressed as mean SD (*p 0.01, cells in chondrogenic vs. those in basal group at the
corresponding time point).
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DISCUSSION
In this study, we characterized the differentiation of
hMSCs into chondrocytes under defined conditions in 3D
alginate gels in vitro, and observed that temporal changes in
gene expression in this system largely paralleled the spatial
pattern of in vivo cartilage maturation in many important
aspects. Specifically, the early gene expression profiles are
similar to that in precursor cells, with the cells showing
progressive increase in markers of chondroprogenitors fol-
lowed by that of mature chondrocytes and then by hyper-
trophic chondrocytes defined by robust upregulation of
collagen type X, alkaline phosphatase, and osteocalcin.
These stage-specific gene profiles show similarities at the
earlier time point to those in fibroblast-like annulus fibrosus
cells and in the later stages to juvenile chondrocytes and
adult nucleus pulposus chondrocytic cells. The findings also
provide insights into stage-specific gene profiles of hMSCs
undergoing chondrogenic differentiation in vitro that may
serve as a useful platform from which to explore differences
in hMSC responsiveness to additional conventional and
unconventional stimuli, such as mechanical load.
The ability of bone marrow stromal cells to differentiate
into various cell phenotypes was first reported in studies in
which colony-forming cells isolated from bonemarrowwere
observed to differentiate under appropriate conditions into
different connective tissues.26 Since then, studies have dem-
onstrated that hMSCs are capable of differentiation along
osteogenic, chondrogenic, or adipogenic lineages both
in vitro and when implanted subcutaneously in SCID mice
under the induction of specific bioactive agents such as
growth factors, cytokines, and ECM.9,17,18,27 Among these
agents, members of TGF-b superfamily (TGF-b1, TGF-b2,
TGF-b3, and BMP-6) have proven to readily induce a se-
quential expression of chondrocytic markers including early





















































FIG. 4. Contour plot of sequential expression of chondrogenic genes in differentiating hMSCs in 3D gels provides a method for
staging the temporal progression of chondrogenesis. RNA retrieved from chondrogenic constructs was assayed for 21 genes by qRT-
PCR, and the magnitude of induction of each gene was standardized to peak levels (considered 100%). The gene expression levels were
divided into 0–20%, 21–40%, 41–60%, 61–80%, and 81–100% levels of peak levels, and plotted in gray scale with the lightest being
0–20% and darkest being 81–100% levels, and genes were arranged in descending order from the one that first reaches 80–100% levels
to one reaching this level last. The analysis revealed both temporal differences and varied patterns of induction of individual genes over
the 24-day period of the experiment. The data also enabled the differentiation to be sequenced into four stages, depicted as stages I–IV
on the basis of when each gene reached its peak level.
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versican core protein, and subsequent upregulation of col-
lagen types II and X, and chondroadherin at different
stages.28–30 Our studies demonstrate a similar induction of
chondrogenic differentiation of hMSCs in alginate gels un-
der defined conditions, which mimics the temporal expres-
sion pattern of cartilage-specific genes in hMSCs in pellet
cultures28–31 and in alginate gel suspension cultures.9,19
In our cell/gel constructs, the chondrogenic hMSCs
assumed a rounded shape, simulating chondrocyte mor-
phology. Additionally, the cell viability remained high
throughout the experimental period, a finding consistent
with previous observations.17,19 Relative to basal levels, cell
proliferation was significantly diminished from days 12 to
24 in both basal and chondrogenic groups. Previous studies
have shown that encapsulation of hMSCs leads to an in-
crease in the number of cells in G0–G1 phase and a con-
comitant decrease in the number of cells in S phase.17,19 This
suggests that the alginate culture system can synchronize
and turn off the proliferation machinery of hMSCs, perhaps
by conferring upon them an appropriate 3D state. Consistent
with our data, this may enable hMSCs to more readily be-
come committed to a differentiation lineage under the de-
fined conditions rather than continue to propagate.
Cartilage development is characterized by serial temporal
and spatial changes in which chondrocytes undergo se-
quential morphological and metabolic transformation in-
volving complicated regulatory and signaling networks that
interweave cell–matrix and intercellular interactions with
a tightly regulated gene expression pattern.32,33 This re-
quires strict coordination between various chondrogenic
factors in order to establish and maintain normal cartilage
physiology.32,33 Our data suggest that sequentially regulated
events that largely simulate in vivo developmental changes
also occur during chondrogenic differentiation of hMSCs in
alginate gels. This observation is supported not only by the
differential expression over time of a variety of genes in
chondrogenic hMSCs, but also by the substantial difference
of cartilage-specific gene expression patterns between
hMSCs cultured in chondrogenic versus basal media. More-
over, our data are in agreement with studies showing that
these genes are highly expressed in chondrogenic hMSCs in
both pellet culture and alginate bead systems, though no
parallel time course comparison between hMSCs in chon-
drogenic versus basal media has been made in previous
studies.17–19
Further evidence of a temporally regulated chondrogenic
gene expression in hMSCs is provided by our qRT-PCR
findings on 21 genes, which enabled us to characterize
chondrocytic differentiation of hMSCs into four stages based
on the time points when each gene first achieved 81–100%
levels. At stage I (days 0–6), collagen types I and VI, Sox 4,
and BMP-2 showed peak expression levels, which were
downregulated thereafter. The gene expression profile dur-
ing this time period was similar to that of the primary
fibroblast-like annulus fibrosus cells. During stage II, gene
expression of COMP, HAPLN1, collagen type XI, and Sox 9
reached peak levels at days 6 to 12, and these were generally
maintained at high expression levels at later stages. At stage
III, which likely represents cells that are analogous to mature
chondrocytes, gene expression of matrilin 3, Ihh, Homeo-
box 7, chondroadherin, and WNT 11 peaked between days
12 and 18. Finally, between 18 and 24 days of differentia-
tion, the cells characterized as stage-IV cells demonstrated
gene profiles similar to those in hypertrophic chondrocytes
with peak expression levels of aggrecan; collagen types II,
IX, and X; osteocalcin; fibromodulin; PTHrP; and alkaline
phosphatase. Cells at stage III and IV showed gene profiles
similar to those in juvenile articular chondrocytes and adult
nucleus pulposus cells.
Overall, our results are consistent with previous studies in
which the temporal expression patterns of collagen types I,
II, VI, IX, and X were analyzed during chondrocytic dif-
ferentiation in vitro.34,35 With respect to the gene expression
levels from each of the two different methods (RT-PCR and
microarray), trends were generally well conserved for those
genes examined by both methods (data not shown). As re-
ported in other relevant in vitro studies, upregulation of
collagen type X in the current system appeared to be tempo-
rally advanced relative to patterns that have been historically
reported in vivo.17,36 The implications of these findings from
a biological as well as tissue engineering standpoint are
currently unclear and only just beginning to be examined.37
As one would expect, a number of key markers, such as
collagen types II and IX (COL2A1 and COL9A2), noted to
be upregulated in our microarray analysis are not novel (data
not shown), in that they are linked, to varying degrees, to
cartilaginous tissues, or to chondrogenesis.38 Additionally,
many other genes previously linked in some way to chon-
drocytic phenotype, including PTHLH/PTHrP, secreted
frizzled-related protein 1 (SFRP1), stanniocalcin 1 (STC1),
proenkephalin (PENK), CLEC3A/CLECSF1, DSPG3,
frizzled-related protein, scinderin, prolactin, matrilin 4, and
gremlin,39–48 were also identified (data not shown). As a
subset of these genes, those that are most commonly be-
lieved to be involved in delaying or inhibiting chondro-
genesis, specifically PTHLH, SFRP1, STC1, and PENK,
tended to be repressed relatively early, while those genes
typically thought to be positive effectors of chondrocyte
maturation, CLEC3A/CLECSF1, COL2A1, COL9A2,
DSPG3, and scinderin, were induced late trends well cor-
related with our model of progressive cellular maturation.
Our array data also revealed the differential expression of
a number of additional genes that may serve as novel stage-
specific differentiation markers for chondrocytic differenti-
ation. Thus, upregulation of scinderin, a known marker of
hypertrophy detected at day 24, together with the RT-PCR
data, suggests that by day 24, cells in our system have begun
to become hypertrophic. More novelly, we posit that the
observed upregulation of gremlin and downregulation of
MFAP5/MAGP-2 at day 24 may be additional evidence in
our array data that a hypertrophic phenotype is emerging at
this stage. Expression of gremlin, a BMP antagonist, has
678 XU ET AL.
been previously detected in a screen for genes expressed in
cartilage growth plate chondrocytes in vivo.40 In contrast,
the extracellular protein MFAP5/MAGP-2 has been recently
shown to act as an agonist ligand for the notch receptor,49
and activation of this receptor by other ligands is well known
to delay or block transition from the prehypertrophic to
hypertrophic stage in developing chondrocytes.50,51 How-
ever, such putative roles for gremlin and MFAP5/MAGP-2
in this particular context are still entirely speculative.
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